Publications by authors named "D Nava-Rodrigues"
Article Synopsis
- * BCL2, an anti-apoptotic protein, is upregulated in these aggressive prostate cancers, which presents a potential target for therapy and highlights the importance of studying its expression in metastatic CRPC (mCRPC).
- * Research shows that BCL2 is more prevalent in AR-negative mCRPC and is linked to poorer survival outcomes; also, its regulation involves DNA methylation and a transcription factor called ASCL1, suggesting the need for combination therapies to improve treatment efficacy.
Therapies that abrogate persistent androgen receptor (AR) signaling in castration-resistant prostate cancer (CRPC) remain an unmet clinical need. The N-terminal domain of the AR that drives transcriptional activity in CRPC remains a challenging therapeutic target. Herein we demonstrate that BCL-2-associated athanogene-1 (BAG-1) mRNA is highly expressed and associates with signaling pathways, including AR signaling, that are implicated in the development and progression of CRPC.
View Article and Find Full Text PDFPurpose: The multi-kinase inhibitor (mKi) regorafenib has demonstrated efficacy in chemorefractory patients with metastatic colorectal cancer (mCRC). However, lack of predictive biomarkers and concerns over significant toxicities hamper the use of regorafenib in clinical practice.
Experimental Design: Serial liquid biopsies were obtained at baseline and monthly until disease progression in chemorefractory patients with mCRC treated with regorafenib in a phase II clinical trial (PROSPECT-R n = 40; NCT03010722) and in a multicentric validation cohort (n = 241).
Article Synopsis
- BAG-1L is a key protein that enhances the androgen receptor's function, playing a role in the progression of prostate cancer.
- Researchers developed a new antibody specific to BAG-1L to study its expression in various prostate cancer stages and breast cancer tissues.
- Higher BAG-1L levels were found in metastases of castration-resistant prostate cancer compared to untreated cases, but no correlation was found between BAG-1L levels and patient outcomes or responses to treatments, highlighting some limitations in the study's findings.
Article Synopsis
- Elevated tissue factor (TF) expression is linked to poor prognosis in various solid cancers, with a systematic analysis conducted to compare its prevalence and localization across multiple tumor types for the first time.
- The study involved patient biopsies from different cancers, revealing that TF was most prominent in pancreatic, cervical, colon, glioblastoma, head and neck squamous cell carcinoma, and non-small cell lung cancer, with varying expression patterns noted in individual cases.
- Findings indicate that while TF is widely present across solid tumors and remains consistent over time for most patients, individual variability exists, suggesting potential implications for disease progression and treatment.